Amphastar (NASDAQ: AMPH) insider lines up stock sale after option exercise

Amphastar Pharmaceuticals (AMPH) insider Floyd Petersen plans to sell 47,101 shares, worth $989,121, via UBS. The shares were acquired through option exercise, with the sale proposed for August 18, 2026. Amphastar has 44.1 million shares outstanding. The sale is under SEC Rule 144, which governs insider share sales.

Original reporting
Published Aug 18, 2026, 9:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 2:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AMPH
Neutral
medium confidence
Mentioned
$AMPH
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AMPHNeutralLow
01

Why it matters

Planned insider selling can pressure short-term sentiment, but the disclosed quantity is small and the filing does not by itself change operating fundamentals.

02

Market read

Traders may monitor AMPH for incremental selling pressure around the proposed sale date, but the magnitude is likely too small to drive a major repricing alone.

03

What to watch

Rule 144 is a notice, not a confirmation of full execution; traders should watch for subsequent Form 144 updates or larger insider transactions to gauge real supply risk.

Relevance 4/10Novelty 3/10Timing: proposed sale date listed as 08/18/2026

Background

The article summarizes an Amphastar Form 144 notice under Rule 144, which outlines conditions for restricted or insider-held shares to be resold publicly.

Company-level read

Ticker impact

$AMPHNeutralMedium confidence
Context

Amphastar filed a Rule 144 notice for Floyd Petersen to sell 47,101 shares after an option exercise, signaling planned insider supply.

Expected impact

Low likelihood of a sustained move; any impact is likely short-lived around the sale window unless follow-on filings show larger selling.

Evidence & confidence

Rule 144 notices are common and do not guarantee execution timing beyond the proposed sale date, and the stated 47,101 shares are small relative to 44.09M shares outstanding.

Market effects

Limited read-through for the specialty pharma sector; this is company-specific insider selling rather than a sector catalyst.

None.

None.

Counterpoint

The sale follows an option exercise for cash, so it may be routine liquidity management rather than a bearish view on fundamentals.

Key entities

  • Amphastar Pharmaceuticals, Inc.

    Subject of the Rule 144 notice, with an insider planned sale of 47,101 shares after option exercise.

  • Floyd Petersen

    Named selling security holder in the Rule 144 notice.

  • UBS Financial Services Inc.

    Identified as the broker/attorney-in-fact in the notice.

Related articles

$AMPHMed

Amphastar Pharmaceuticals Q3 Earnings Call Highlights

Amphastar Pharmaceuticals reported Q3 gross margin decline to 48% from 51% YoY, citing lower pricing for BAQSIMI and increased manufacturing costs. The company expects higher remediation expenses in coming quarters. Amphastar aims to reduce a $12.5M backlog and sees continued lidocaine demand. It remains on track for potential 2027 launches of insulin aspart biosimilar and AMP-018, with other pipeline updates. Operating cash flow was $43.3M, and the board authorized $50M for share repurchases.

$AMPHHigh

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026 ​ - Net revenues of $207.6 million for the three months ended September 30, 2026 ​ - GAAP net income of $37.8 million, or $0.87 per share, for the third quarter ​ - Ad